* Valeant's patient access and pricing committee announces pricing for Siliq(brodalumab) as the lowest priced injectable biologic for moderate-to-severe plaque psoriasis
* Valeant - sales and marketing of Siliq are expected to commence in U.S. During second half of 2017
* Valeant - decided to list Siliq injection, at $3,500 per month
* Valeant - Siliq will also be included in company's patient access program to further offer financial support and access to patients Source text for Eikon: Further company coverage: VRX.TO
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.